There have been some noticeable changes in studies of the endocrinology of breast cancer in the last two decades. In the early 1950s, methods for the determination of most of the hormones thought to be important in the etiology and clinical course of the disease were either bad or non-existent. In these circumstances, extrapolation of the results obtained in laboratory animals to man was free from the tiresome constraint imposed by experimental work. By 1955, new analytical methods meant that the role of some of the steroid hormones (in particular the cestrogens) could be investigated, but so ingrained were the concepts derived from animal models that the first surveys of endocrine status in man were based on small numbers of heterogeneous patients, in the expectation that the presumptive abnormalities would be so obvious that the most casual experiments would reveal them. Some twenty years later there is still very little clear knowledge about the endocrinology of breast cancer but at least some of the difficulties are now apparent. The variability within and between women is better appreciated, very much larger numbers of patients or normal women are being studied, and a much wider endocrinological spectrum is being measured (for reviews see Bulbrook & Strong 1959 , Bulbrook 1965 , Wang etal. 1972 .
The present situation is still chaotic. There are, however, three interesting leads among the icefloes. The first of these is the attempt by Cole & MacMahon (1969) to interpret the results of an impressive epidemiological study in endocrinological terms; the second is the finding that endocrine abnormalities precede the clinical appearance of the disease ; and the third is that there is now strong presumptive evidence that a virus is the initiating agent in man (Moore et al. 1971 , Schlom et al. 1971 ). It would be highly desirable to be able to integrate the findings concerning epidemiological, endocrinological and viral factors but there are simply not enough data to make this possible. All that can be done is to describe the findings and to suggest ways in which these fields may be linked.
One of the most important and intriguing findings in recent years is the demonstration by MacMahon et aL (1970) that women who have pregnancies early in their reproductive life have a marked reduction in lifelong risk of breast cancer, compared with that of nulliparous women or women having first pregnancies later than the age of 35 years. MacMahon et al. (1970) state:
'The striking reduction of risk associated with a single pregnancy of only 9 months' duration implies that the reduction is not explained by decreased exposure to causative agents during the pregnancy alone.' Cole & MacMahon (1969) have put forward a hypothesis in an attempt to accommodate their epidemiological findings to those of other workers and to experimental and clinical evidence. In brief they suggest that cestriol inhibits the carcinogenic action of aestrone and cestradiol. In pregnancy, very large amounts of oestriol are produced and might therefore account for the protective effects of early pregnancy. This theory, assigning an important role to the cestrogens in mammary carcinoma, would also explain the reduction in risk in women who are oophorectomized before the age of 40, and the fact that pregnancy increases incidence in mice, since the pregnant mouse produces aestrone and oestradiol but no cestriol.
A signal virtue of the hypothesis of Cole & MacMahon (1969) is that it can be tested experimentally. Already, cestriol:cestrone and cestriol: cestradiol ratios have been compared in Asians with a low incidence of breast cancer and in North American women with a high incidence (MacMahon et al. 1971 ). In women aged 15-19 years the oestriol ratio is significantly higher in Asians than in North Americans; in women aged 35-39, the Asian ratios are higher but not significantly so.
The evidence against the cestrogens playing an important role in the etiology of the disease is discussed later, but, whether this is so or not, any hypothesis concerning endocrine aspects of breast cancer must explain the epidemiological findings of MacMahon et al. (1970) .
In contrast to this epidemiological work, an endocrinological study was set up in Guernsey in 1961 to test the thesis that low androgen excretion might be a factor in the pre-clinical stages of the disease. A single 24-hour urine specimen was collected from each of 5000 normal volunteers aged 30-55 years. Subsequently, 27 of these women had breast cancer. The amounts of urinary androgen and corticosteroid metabolites that they excreted before the disease became manifest were compared with those excreted by women without breast cancer, and it was shown that the pre-cancer cases excreted significantly less androsterone and etiocholanolone before diagnosis than the controls. The abnormality occurred up to nine years before diagnosis and was not related to age over the range studied. This finding indicates that a deficiency in androgen excretion is not likely to be a late event in the history of the disease, and, in this respect, the Section ofOncology result would be in agreement with Cole & MacMahon's statement that events very early in life determine risk.
If the results of the Guernsey sample are correct, it should be possible to predict that other groups of women known to be at risk (from epidemiological studies) will be likely to excrete subnormal amounts of androgen metabolites, unless there are multiple endocrine pathways, each associated with enhanced risk (see Bulbrook & Hayward 1967) .
Women with some types of benign breast disease have an increased risk of breast cancer. Androgen metabolite excretion has been measured in such patients and it has been found that those aged 21-30 years excrete subnormal amounts of androsterone and oetiocholanolone. The abnormality is less marked in women aged 31-40, and disappears in women in the fifth decade. If risk of breast cancer is inversely proportional to androgen metabolite excretion, then the youngest women in this survey would be expected to be at the greatest risk. This is precisely what has been shown by Warren (1940) , who found that the earlier chronic mastitis was found the greater the risk of subsequent breast cancer. These findings provide excellent indirect evidence that the amounts of androgen excreted are related to risk of breast cancer.
There is little argument concerning the claim that unaffected sisters of breast cancer patients have an enhanced risk of breast cancer, although there is some dispute concerning the precise degree of risk. Androgen metabolite excretion has been measured in 35 unaffected sisters. Only in women aged 31-40 years were subnormal amounts of these compounds found. In older sisters the amounts differed little from the normal. This finding may be relevant to the recent results of Anderson (1971) on familial breast cancer.
There are at least two explanations for these findings. The first is that abnormalities in androgen excretion are simply a marker for other heritable risk factors (which may not necessarily be endocrine). The second is that endocrine function is genetically determined and that defective androgen production is inherited.
The interpretation ofthe results ofthe Guernsey experiment and their integration with the findings of MacMahon et al. (1970) in terms of the total endocrine status of the women at high risk can only be speculative at this time. One critical point is whether the women with a normal or high excretion of androgens are also characterized by a high aestriol ratio. If this were so, it might be possible to relate the findings of the prospective study in Guernsey to the main features of Cole & MacMahon's hypothesis. On this basis, it would be predicted that women with pregnancies early in life should excrete normal amounts of androgen metabolites and, conversely, women at risk, with a subnormal excretion of androgens, might be expected to excrete less aestriol in relation to aestradiol and cestrone. This should not be difficult to determine experimentally.
However, there is another interpretation of the present results from the Guemsey experiment that would be entirely at variance with the Cole-MacMahon hypothesis. Adlercreutz et al. (1967) have shown a direct relationship between the amounts of androgens excreted in the urine and the amounts of cestrogen metabolites. It could be supposed, therefore, that a subnormal excretion of androgens in the pre-cancer patients might indicate a subnormal cestrogen excretion. The data on this point are fragmentary: in 5 precancer cases plasma oestradiol values were found to be in the normal range, and in young women with benign breast disease the plasma oestradiol levels were either normal or at the lower end of the normal range (Miss M C Swain, 1971, personal communication) . Neither plasma nor urinary cestriol values have been measured in such cases; indeed the concentration of free cestriol in blood is likely to be so small that there will be very considerable technical difficulties in measuring it, since Adlercreutz & Liiukkainen (1968) were unable to find free cestriol in a 1 litre sample of blood obtained at term. The results of studies of the urinary excretion of cestrogen metabolites are so variable that any interpretation can be placed upon them with a little judicious selection (see Wang et al. 1972) . For a variety of reasons, the determination of cestrogen status in pre-cancer cases would be highly desirable. The thesis that a deficiency in cestrogen secretion may be associated with increased risk appears to contradict the findings of Feinleib (1968) that oophorectomy for reasons other than breast cancer reduces subsequent risk, if carried out early enough. But women so treated almost certainly form a distinct section of the normal population, in endocrinological terms, and may have been exposed to high levels of cestrogens for many years before being treated by oophorectomy. If this is so, they may then be directly comparable to the early pregnancy group. In the fullness of time, some evidence on the carcinogenic effects of early exposure to large amounts of (estrogen should be available from studies of the risk of breast cancer associated with use of steroid contraceptives.
If the aestrogens are displaced from their historic role of the key hormones in human breast cancer, the next best substitute might be prolactin. There is now a considerable amount of evidence that prolactin is important in tumour growth in some strains of rats and mice (Boot 1970 , Nagasawa & Yanai 1970 , Cassell et al. 1971 . Pearson et al. (1969) have found that the DMBA-induced rat mammary carcinoma is dependent on prolactin. In the oophorectomized, adrenalectomized, hypophysectomized rat, prolactin alone will stimulate tumour growth; cestradiol benzoate is without effect.
However, Hilf et al. (1971) administered fluphenazine to Fisher rats bearing the R3230 AC mammary tumour and found that while the normal breast grew, the tumour decreased in weight. Fluphenazine would be expected to increase prolactin secretion. There is also the clinical paradox that while hypophysectomy brings about remission of advanced metastatic disease in some women, an effect assumed to be due to the cessation of pituitary and adrenal secretion, stalk section of the pituitary may have the same beneficial effects (Ehni & Eckles 1959) and prolactin secretion might be expected to be high in such patients. Both animal models may be relevant to human breast cancer if the concept that there may be several endocrine pathways associated with enhanced risk is correct. What is now required are direct measurements of plasma aestrogen, progesterone and prolactin, especially in women characterized by an abnormal excretion of androgen metabolites. In addition, studies of breast structure in such women might be useful, especially in the light of the results of Foote & Stewart (1945) , who found fewer breast lobules in pre-menopausal women with breast cancer than in their controls, a result that is not in accord with any endocrine theory invoking a hypersecretion oftrophic hormones.
There seems to be a measure of agreement that hormones are not initiators of the transformation of normal breast cells into malignant ones. An initiating agent is required, such as the mammary tumour virus (Bonser et al. 1961 ). The hormones act as modifiers of viral action but in this role they may be so powerful that the effects of the initiating agent may be virtually abolished (Furth 1964) . Recently it has been shown that some human milk contains particles that are physically identical to mouse mammary tumour virus and that these particles are found more often in milk from women with affected kindred than in the general population (Moore et al. 1971) . There is also strong biochemical evidence that these particles are RNA virions and that they can be found in the majority of human breast tumours (Schlom et a!. 1971). While there is no direct evidence that this virus is the initiating agent in man, it seems highly probable that this is its role.
It now becomes necessary to re-examine endocrinological studies in the light of the findings of Moore et al. (1971) . It may be true that in mice there are no tumours without the presence of virus; it is certainly true that virus may be present without the development of tumours, and that other factors (Bittner 1943 ) have a profound influence. In man, therefore, a virus may be an essential factor but endocrine status may be the determinant ofwhether or not a tumour develops. This has an important bearing on future epidemiological and endocrinological studies. If both viral infection and a particular endocrine pattern are required for oncogenesis, then studies of either factor alone might produce misleading interpretations. For example, women in the Guernsey experiment who excreted less than 500 ,ug of aetiocholanolone might be expected to be at high risk compared with those excreting 1-2 mg/24 h. In the absence of tumour virus, the former women might, in fact, have no enhancement of risk. Early pregnancies might exert their effects not by direct endocrinological stimuli but by modifying viral action.
We have now arrived back at the introductory paragraphs of this article in that, once again, speculation is all that is possible in the absence of data. It is to be hoped that new assays for most of the important hormones and new methods for detecting mammary tumour virus will render such speculations unnecessary in the near future.
